| |  Online-Ressource |
|---|
| Verfasst von: | Figueroa Vazquez, Vianihuini [VerfasserIn]  |
|---|
| | Ko, Jonathan [VerfasserIn] |
|---|
| | Breunig, Christian [VerfasserIn] |
|---|
| | Baumann, Anja [VerfasserIn] |
|---|
| | Giesen, Nicola [VerfasserIn] |
|---|
| | Palfi, Aniko [VerfasserIn] |
|---|
| | Müller, Christoph [VerfasserIn] |
|---|
| | Lutz, Christian [VerfasserIn] |
|---|
| | Hechler, Torsten [VerfasserIn] |
|---|
| | Kulke, Michael [VerfasserIn] |
|---|
| | Müller-Tidow, Carsten [VerfasserIn] |
|---|
| | Krämer, Alwin [VerfasserIn] |
|---|
| | Goldschmidt, Hartmut [VerfasserIn] |
|---|
| | Pahl, Andreas [VerfasserIn] |
|---|
| | Raab, Marc-Steffen [VerfasserIn] |
|---|
| Titel: | HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells |
|---|
| Verf.angabe: | Vianihuini Figueroa-Vazquez, Jonathan Ko, Christian Breunig, Anja Baumann, Nicola Giesen, Anikó Pálfi, Christoph Müller, Christian Lutz, Torsten Hechler, Michael Kulke, Carsten Müller-Tidow, Alwin Krämer, Hartmut Goldschmidt, Andreas Pahl, and Marc S. Raab |
|---|
| Jahr: | 2021 |
|---|
| Umfang: | 13 S. |
|---|
| Fussnoten: | Published online first: December 9, 2020 ; Gesehen am 08.09.2021 |
|---|
| Titel Quelle: | Enthalten in: Molecular cancer therapeutics |
|---|
| Ort Quelle: | Philadelphia, Pa. : AACR, 2001 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 20(2021), 2, Seite 367-378 |
|---|
| ISSN Quelle: | 1538-8514 |
|---|
| Abstract: | Despite major treatment advances in recent years, patients with multiple myeloma inevitably relapse. The RNA polymerase II complex has been identified as a promising therapeutic target in both proliferating and dormant cancer cells. Alpha-amanitin, a toxin so far without clinical application due to high liver toxicity, specifically inhibits this complex. Here, we describe the development of HDP-101, an anti-B-cell maturation antigen (BCMA) antibody conjugated with an amanitin derivative. HDP-101 displayed high efficacy against both proliferating and resting myeloma cells in vitro, sparing BCMA-negative cells. In subcutaneous and disseminated murine xenograft models, HDP-101 induced tumor regression at low doses, including durable complete remissions after a single intravenous dose. In cynomolgus monkeys, HDP-101 was well tolerated with a promising therapeutic index. In conclusion, HDP-101 safely and selectively delivers amanitin to myeloma cells and provides a novel therapeutic approach to overcome drug resistance in this disease. |
|---|
| DOI: | doi:10.1158/1535-7163.MCT-20-0287 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1158/1535-7163.MCT-20-0287 |
|---|
| | Volltext: https://mct.aacrjournals.org/content/20/2/367 |
|---|
| | DOI: https://doi.org/10.1158/1535-7163.MCT-20-0287 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1753173795 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells / Figueroa Vazquez, Vianihuini [VerfasserIn]; 2021 (Online-Ressource)
